Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic Coronavirus Disease 2019: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
- Journal:
- Clinical Infectious Diseases
- Published:
- DOI:
- 10.1093/cid/ciaf265
- Affiliations:
- 3
- Authors:
- 17
| Institutions | Authors | Share |
|---|---|---|
| Invivyd Inc., United States of America (USA) | 0.88 | |
| Duke University Health System, United States of America (USA) | 0.06 | |
| Jadestone Clinical Research, LLC, United States of America (USA) | 0.06 |